News about Clinical Trials

Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer

Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.

Clinical Trials | 08/01/2026 | By News Bureau |  136

Acesion Pharma Begins Phase-II Trial of AP31969 in Atrial Fibrillation

The Phase-II study of AP31969 by Acesion Pharma will evaluate the efficacy and safety of AP31969, a first-in-class oral SK ion channel inhibitor, in reducing atrial fibrillation burden using continuous cardiac rhythm monitoring.

Clinical Trials | 08/01/2026 | By News Bureau

China Updates Ivonescimab Label After NSCLC Survival Gains

China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />

Clinical Trials | 07/01/2026 | By News Bureau |  212

HUTCHMED Begins Phase III Trial of Surufatinib-Camrelizumab Combo in Pancreatic Cancer

HUTCHMED has initiated the phase-III stage of its phase-II/III clinical trial in China evaluating a combination regimen of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, with the first patient dosed on 30 December, 2025.

Clinical Trials | 05/01/2026 | By News Bureau

FibroBiologics Files IND Application with US FDA for CYPS317 in Psoriasis

FibroBiologics has filed an Investigational New Drug (IND) application with the US FDA for CYPS317, marking a key step towards initiating clinical development of the therapy for psoriasis, supported by encouraging preclinical data showing reduced disease severity and relapse.

Clinical Trials | 03/01/2026 | By News Bureau

XORTX Unveils New Research on Genome-Wide Pathways in Gout

XORTX Therapeutics highlighted findings from recent independent, peer-reviewed research showing that multiple genetic factors are linked to over-expression of Xanthine Oxidase (XO), chronically elevated blood uric acid levels, and gout—further reinforcing the company’s strategy of targeting XO to treat gout, kidney, and related diseases.

Clinical Trials | 01/01/2026 | By News Bureau

Senhwa Expands Oncology Manufacturing Focus With CX-5461 - ADC Combination Trial

Senhwa Biosciences, Inc. has announced a significant clinical development milestone with its first-in-class investigational agent Pidnarulex (CX-5461) set to be evaluated in combination with the antibody–drug conjugate trastuzumab deruxtecan (Enhertu) in a phase 1b clinical trial.

Clinical Trials | 30/12/2025 | By Darshana

Diamyd Medical Advances Type I Diabetes Phase III Efficacy Readout by Nine Months

Diamyd Medical has aligned with the US FDA to accelerate the primary efficacy readout of its Phase 3 DIAGNODE-III trial in type 1 diabetes from 24 to 15 months, enabling results to be available nine months earlier than previously planned.

Clinical Trials | 30/12/2025 | By News Bureau

KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC

KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.

Clinical Trials | 18/12/2025 | By News Bureau

US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer

The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.

Clinical Trials | 12/12/2025 | By Akanki |  180